AARDEX Group Partners with Industry Leaders on DiMe’s V3+ Framework Project to Enhance Usability of DHTsExtending the Verification, Analytical Validation, and Clinical Validation (V3+) Framework Project will ensure digital clinical measures and products meet the needs of larger audiences3 May 2023 -- Liege, Belgium --
Adherence specialists AARDEX Group are proud to announce its partnership with other industry leaders on DiMe’s new Extending the Verification, Analytical Validation, and Clinical Validation (V3+) Framework project.
Organisations are taking digital clinical measures and products to scale, meaning digital health technologies (DHTs) must meet the needs of larger audiences. DiMe's existing V3 Framework is the go-to guide for evaluating whether sensor-based DHTs are fit-for-purpose from a technical, scientific and clinical performance of the product perspective.
The goal of the new V3+ project is to build on this success by adding evidence-based components that ensure DHTs meet the needs of all users through the application of best practices in usability, human factors and human-centred design.
AARDEX Group is representing an ecosystem of a partnership of companies, Medmix, Schreiner MediPharm and Westrock, on the project group.
Bernard Vrijens, CEO & scientific lead at AARDEX Group, said: “This is a great team and a fast-moving project which we are delighted to be part of. Medication adherence packaging is already very high in terms of usability compared to other approaches such as video directly observed therapy (VDOT). AARDEX Group looks forward to bringing its extensive experience in usability and human factor studies to the V3+ Framework Project.”
The V3+ project will help ensure DHTs meet the necessary industry and regulatory standards for usability, while drawing on the principles of diversity, equality and inclusion. It will also ensure data generated by DHTs in the real-world conditions of decentralised clinical trials (DCTs) and healthcare delivery is trustworthy for clinical, regulator and payer decision-making.
"Since we published V3 in 2020, the framework has emerged as the go-to guide for evaluating whether sensor data is accurate and precise, true and informative. It has been accessed over 30,000 times, used by over 130 teams including national and international government agencies and cited over 150 times in the scientific literature," said Jessie Bakker, programme director at DiMe. “We’re now seeking to build on this incredible success by evaluating and defining best practices for user-centred design, usability and human factors engineering of digital medicine technologies, ensuring scalability while meeting the needs of all users they are designed to help."About AARDEX Group
At AARDEX Group, we believe in the power of digital solutions to revolutionise the way we measure and manage medication adherence. We're not just talking the talk; we're walking the walk as the global leader in this space. Our cutting-edge technology, MEMS Adherence Software (MEMS AS), is the cornerstone of a comprehensive ecosystem designed to deliver accurate, data-driven adherence analytics across all forms of drug administration. But we don't stop there. Our team is dedicated to continuously innovating and pushing the boundaries of what's possible in the world of clinical trials. Our mission is simple yet ambitious: to empower patients and revolutionise the way we approach medication adherence in clinical trials through the use of data and technology. At AARDEX, we're not just making a difference; we're leading the charge. Visit: www.aardexgroup.com